Evidence mapPaperPMID 33678312Full record

ReviewSeminars in nephrology2020

Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.

Abutaleb Ahsan Ejaz, Takahiko Nakagawa, Mehmet Kanbay, Masanari Kuwabara, Ada Kumar, Fernando E Garcia Arroyo, Carlos Roncal-Jimenez, Fumihiko Sasai, Duk-Hee Kang, Thomas Jensen and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Chromene flavanones fromFrontiers in pharmacology · 2025
    Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 4 countries.

Abutaleb Ahsan EjazDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Takahiko NakagawaDepartment of Nephrology, Rakuwakai Otowa Hospital, Kyoto, Japan.
Mehmet KanbayDivision of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Masanari KuwabaraDepartment of Cardiology, Intensive Care Unit, Department of Cardiology, Toranomon Hospital, Tokyo, Japan.
Ada KumarRenal Section, Horizon Therapeutics, Lake Forest, IL.
Fernando E Garcia ArroyoDepartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología "Ignacio Chávez," Mexico City, Mexico.
Carlos Roncal-JimenezDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO.
Fumihiko SasaiDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO.
Duk-Hee KangDivision of Renal Diseases, Ewha University, Seoul, Korea.
Thomas JensenDivision of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Ana Andres HernandoDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO.
Bernardo Rodriguez-IturbeInstituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán," Mexico City, Mexico.
Gabriela GarciaDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO.
Dean R TolanDepartment of Biology, Boston University, Boston, MA.
Laura G Sanchez-LozadaDepartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología "Ignacio Chávez," Mexico City, Mexico.
Miguel A LanaspaDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO.
Richard J JohnsonDivision of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: richard.johnson@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · USInstituto Nacional de Cardiología · MXBoston University · USHorizon Therapeutics (United States) · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXKoç University · TRRakuwakai Otowa Hospital · JPToranomon Hospital · JPUniversity of Florida · US

Funding

NIDDK NIH HHS R01 DK108408NIDDK NIH HHS R01 DK108859
6 · The paper itself

Abstract

Kidney disease, especially when it is associated with a reduction in estimated glomerular filtration rate, can be associated with an increase in serum urate (uric acid), suggesting that hyperuricemia in subjects with kidney disease may be a strictly secondary phenomenon. Mendelian randomization studies that evaluate genetic scores regulating serum urate also generally have not found evidence that serum urate is a causal risk factor in chronic kidney disease. Nevertheless, this is countered by a large number of epidemiologic, experimental, and clinical studies that have suggested a potentially important role for uric acid in kidney disease and cardiovascular disease. Here, we review the topic in detail. Overall, the studies strongly suggest that hyperuricemia does have an important pathogenic role that likely is driven by intracellular urate levels. An exception may be the role of extracellular uric acid in atherosclerosis and vascular calcification. One of the more striking findings on reviewing the literature is that the primary benefit of lowering serum urate in subjects with CKD is not by slowing the progression of renal disease, but rather by reducing the incidence of cardiovascular events and mortality. We recommend large-scale clinical trials to determine if there is a benefit in lowering serum urate in hyperuricemic subjects in acute and chronic kidney disease and in the reduction of cardiovascular morbidity and mortality in subjects with end-stage chronic kidney disease.

Indexed as

Cardiovascular DiseasesHyperuricemiaRenal Insufficiency, ChronicVascular CalcificationHumansRisk Factorsacute kidney injuryallopurinolcardiovascular mortalitychronic kidney diseaseHyperuricemia

Identifiers

PMID33678312
PMCPMC7951176
OpenAlexW3134981847

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.